Compare SIBN & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIBN | ZVRA |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 622.3M | 653.2M |
| IPO Year | 2018 | 2015 |
| Metric | SIBN | ZVRA |
|---|---|---|
| Price | $14.66 | $10.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $23.88 | $23.00 |
| AVG Volume (30 Days) | 765.5K | ★ 1.3M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.33 | ★ 159.21 |
| EPS | N/A | ★ 0.60 |
| Revenue | $67,301,000.00 | ★ $106,470,000.00 |
| Revenue This Year | $16.95 | $37.27 |
| Revenue Next Year | $14.93 | $53.42 |
| P/E Ratio | ★ N/A | $17.05 |
| Revenue Growth | 21.53 | ★ 350.91 |
| 52 Week Low | $11.48 | $7.16 |
| 52 Week High | $21.89 | $13.16 |
| Indicator | SIBN | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 58.77 | 51.08 |
| Support Level | $14.42 | $8.30 |
| Resistance Level | $14.85 | $11.07 |
| Average True Range (ATR) | 0.81 | 0.64 |
| MACD | 0.22 | -0.09 |
| Stochastic Oscillator | 91.60 | 26.10 |
SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.